Why Abzena?

At Abzena, we have a focused approach to get it right from the start. Find out what sets us apart by downloading our brochure or reading more below.

We share knowledge and insights. We ensure seamless transitions.
We anticipate and meet challenges, advocating our customers’ successes.

Focused biopharmaceutical CDMO + CRO with:

  • Fully integrated early R&D through commercial capabilities
  • High-quality & trusted data that drives development
  • Streamlined regulatory support tailored to your program

Capabilities ranging from:

→ Early-Stage Research & Discovery, Design & Lead Selection
→ Robust Bioassays & Analytics, & Immunogenicity Assessments
→ Bioconjugation, ADCs & Chemistry
→ Antibody Engineering &Developability
→ Mammalian Cell Line Development

→ Linker Payload Design & Synthesis
→ Analytical Method & Formulation Development
→ Process Development & cGMP Manufacturing up to 2000L
→ Technology Transfer & Scale-Up
→ Regulatory Support

Comprehensive support for:

  • Monoclonal Antibodies (mAbs)
  • Antibody-Drug Conjugates (ADCs)
  • Antibody-Oligonucleotide Conjugates (AOCs)
  • Radionuclide Antibody-Conjugates (RACs) & Radionuclide Drug-Conjugates (RDCs)
  • Bispecific Antibodies (bsAbs)
  • Fusion Proteins
  • Growth Factors
  • Cytokines
  • Recombinant & Conjugate Vaccines
  • Nanoparticles
  • Biosimilars

What sets Abzena apart?

It’s our approach. We are focused on getting it right from the start and providing a de-risked and streamlined development pathway for our customers.

From early discovery through commercial, our experienced scientists work with you side-by-side, functioning seamlessly as part of your team — using real-world insights to bring new ideas to the table and then turning them into action. With quality at the front of everything we do, we plan the best route, steering your drug program toward regulatory approval, and getting it quickly and effectively to patients.

Access our corporate brochure to learn more!

Access to Genuine Scientific & Technical Experts

We have over 20 years of experience in delivering solutions at each stage of the development lifecycle from early-stage research and discovery, through lead candidate selection, and onward into process development and GMP manufacture.

Unlike most other service providers, we can provide technical and scientific support that truly spans early-stage research through process development and GMP manufacturing under a single organization to better ensure that the TPP can be achieved. Our global scientific teams have extensive experience in overcoming some of the most challenging and complex biologic and bioconjugate programs, making us the perfect partner for novel and disruptive technologies that other CDMOs may shy away from.

Proactive Problem Solving to Ensure Downstream Success

Our experienced team is focused on getting it right from the start. We identify and address challenges early in drug design to better ensure downstream clinical and commercial success. We also have expertise in fixing and optimizing drugs in later stage development to rescue them from the drug development graveyard.

Diverse & Interconnected Expertise Under a Single Organization

With capabilities ranging from bioassays to cell line development, bioconjugation and clinical and commercial manufacturing, all under one organization, we can reduce the white space in the development path, which ultimately minimizes risk, reduces costs and accelerates timelines for our customers.

As an integrated service provider, we accelerate timelines through the ease of technical and materials transfer, and improved scheduling. Better workflows and processes can also be attained through improved knowledge transfer between internal multidisciplinary experts and the development of a deep understanding of the drug as it progresses from target to lead selection and process development and manufacture.

Driven by Innovation to Streamline Development

Our team is always seeking new ways to innovate and streamline development for our customers. Our extensive scientific capabilities and proprietary solutions like EpiScreen® 2.0, Composite Proteins™, Composite Human Antibodies™, AbZelect™ & AbZelectPRO™, ThioBridge™, and LabZient™ are designed to give your program the best chance of clinical and commercial success.

  • EpiScreen® 2.0 — an extensive suite of bioinformatic and primary human cell-based assays for immunogenicity assessment to inform of potential safety and efficacy risks in the clinic.
  • Composite Human Antibody™ — a platform used for designing safer, more effective, humanized antibodies.
  • Composite Proteins™ — a deimmunization technology that designs safer and more effective therapeutic proteins, devoid of human T cell epitopes, to minimize potential immunogenicity in patients without compromising activity.
  • AbZelect™ & AbZelectPRO™ — high-yielding cell line development (CLD) platforms for accelerating the generation of production cell lines for manufacture of antibodies and recombinant proteins.
  • ThioBridge™ — a next-generation conjugation linker technology proven to enhance ADC development by overcoming issues with existing technologies to improve stability, potency, and efficacy.
  • LabZient™ — our analytical platform that combines predictive in-silico evaluation with laboratory methods to de-risk the application of platform analytical procedures and expedites the pathway to IND.

We share knowledge and insights, ensuring seamless transitions, and anticipate and address challenges on the horizon.

Most importantly, we produce results.

1400+

Lead candidates discovered, and designed.

85%

Customers request additional work.

70+

Integrated programs delivered in support of INDs.

4x programs scaling to PPQ and commercial production. 100+ production cell lines developed.

 

 

What makes Abzena a unique partner for you?

At Abzena, our unique structure and our values helps us build collaborative and long-lasting relationships with our partners. We believe partnering with other organizations allows scientific innovation to flourish. We are a trusted partner across all phases of drug discovery and development, focused on growing together. Our ultimate goal is to get next-generation medicines to patients, faster.